General Neurology
Pathologic yawning
Apr. 30, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
The figure depicts the use of Sabin OPV (mOPV2 and tOPV) for outbreak response and introduction of nOPV2 in March 2021. The data are from July 1, 2016 to December 31, 2023.
Abbreviations: cVDPV2, type 2 circulating vaccine-derived type 2 monovalent oral poliovirus vaccine; tOPV, trivalent oral poliovirus vaccine; bOPV, bivalent oral poliovirus vaccine; mOPV2, type 2 monovalent oral poliovirus vaccine; nOPV2, novel type 2 oral poliovirus vaccine.
(Source: Lopez Cavestany R, Eisenhawer M, Diop OM, Verma H, Quddus A, Mach O. The last mile in polio eradication: program challenges and perseverance. Pathogens 2024;13[4]:323. Based on a figure from: Bandyopadhyay AS, Zipursky S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect Dis 2023;23[2]:e67-71. Creative Commons Attribution 4.0 International [CC BY 4.0] license, creativecommons.org/licenses/by/4.0.)